Altitude Acquisition Corporation (ALTU) Quote

Why a CH7 Pink Sheets stock could rally to 0.14 from 0.01? Anyway I
am holding over 9M cheap shares and ready to make huge profits...

Today is Tuesday and no good news....

what's going on here?

NASDAQ Busted ALTU Trades; Class Action Suit?
How can the below after-market trade reversal by NASDAQ 10/28/09 be considered fair and reasonable?
From E*trade,
Your trade inquiry for order #5307 sell 60,000 ALTU at $0.26 has been reviewed and completed.
There were a number of trades that were reversed by NASDAQ which included your order. From nasdaqtrader.com:
'Pursuant to Rule 11890(b) NASDAQ, on its own motion, has determined to cancel all trades in security Altus Pharmaceuticals Inc (ALTU) at or above $0.2497 that were executed between 15:12:00 and 15:14:00 ET. This decision cannot be appealed. MarketWatch has coordinated this decision with other UTP exchanges. NASDAQ will be canceling trades on the participant's behalf.'”
E*TRADE Account Alert
Wed Oct 28 16:06:32 2009 - Sell 60000 ALTU Execution Reversed
Dear Valued Investor,
Account: xxxx- The reported execution of your Sell order for 60000 ALTU at $0.26 on 10/28/09 was incorrect. Your order execution has been reversed. See order # 5307 for details.

tested .09 three times.

No complain here but there has to be more then just chart play here...IMHO some thing is brewing and we may find out what it is after the trading today or Monday before opening...all IMHO

ALTUQ on Mon

http://www.otcbb.com/asp/dailylist_detail.asp?d=11/20/2009&mkt_ctg=NON-OTCBB

MK

ALTU is going to .175 look at these charts

If you look at the chart just on technicals, you can see that it will more likely go to around $0.175 today. Accumulating now for the run.

3 month daily

http://stockcharts.com/h-sc/ui?s=altu&p=...

5 Day 15 minute

http://stockcharts.com/h-sc/ui?s=ALTU&p=...

So IMHO I think that it will take off to .175 once it hits the 20 mark on the FAST STO, the MM has needed shares all day, so he has them now when he dropped the price to .09, he collected a lot of shares then. Get ready for the next run. Put the word out now to get in before it goes.

I got no idea, volume is high and pps goes up.
Hopefully some good news on the horizon ;)

What is happening here??????

holy crap look at all the shorts that are posting at .0501!!!

Looks like this may be bound for the otc.

I see this is CH 7 now.

I see that good call, but why the big rebound???

New 52-week low 0.01 was created today! Over 2M shares dumped below
0.02 in this morning pre-market session. CH7 filed as I predicted!

DAMM@!#$!!!!! can't believe i missed em...arghhh!

yep

WERE THE 1C TRADES REAL??

Will this CH7-ready trash hit the new low 0.01 soon? I do think so!

Hopefully there will be some good news after the market close.

ALTU going mad!

Nice recovery here ;)

Another new 52-week low 0.11 was created two days ago! Sell the pos
scam ASAP before the CH7 filed formally. Only worth 0.01 per share!

New 52-week low 0.125 was created a couple of days ago! Sell at bid
ASAP before the pos scam hits another new low...

New 52-week low 0.13 was created today! Sell at the bid ASAP before
the pos scam files the CH7. The stock is only worthing .01 a share!

Why people pay 0.14 ~ 0.19 per share to buy a soon CH11/CH7 trash?
The share is only worth 0.01 per share based on the assets sale...

Altus Pharmaceuticals Inc. (ALTU)


Friday, September 25, 2009
BUYINS.NET: Altus Pharmaceuticals (ALTU) Has Been Added To Naked ...


Altus Pharmaceuticals Inc. (NASDAQ: ALTU), together with its subsidiaries, focuses on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. Its lead product candidates include ALTU-238, completed Phase II clinical trial in adults, is a crystallized formulation of human growth hormone for the treatment of hormone deficiency and related disorders; and ALTU-237, completed Phase I clinical trial, which is used for the treatment of hyperoxalurias and kidney stones. The companyais preclinical research and development programs include ALTU-236, an orally-administered enzyme replacement therapy product candidate designed to reduce the long-term effects associated with excess levels of phenylalanine; and ALTU-242, an orally-administered enzyme product candidate designed to reduce the long-term effects associated with excess levels of urate, which precipitates and forms crystals in joints causing a painful erosive arthritis, known as gout. Its product candidates are designed to substitute a protein that is in short supply in the body, degrade toxic metabolites in the gut, and remove them from the blood stream. Altus Pharmaceuticals has a license agreement with Cystic Fibrosis Foundation Therapeutics, Inc. to use its intellectual property to develop, manufacture, and commercialize any product using, in any combination, the three active pharmaceutical ingredients which comprise Trizytek. Altus Pharmaceuticals Inc. was formerly known as Altus Biologics Inc. and changed its name to Altus Pharmaceuticals Inc. in May 2004. The company was incorporated in 1992 and is based in Waltham, Massachusetts. There is a failure to deliver in shares of ALTU.

Guess I should have paid more attention:

http://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=6798476-839-6173&type=sect&TabIndex=2&companyid=688092&ppu=%252fdefault.aspx%253fsym%253dALTU

On September 11, 2009, Altus Pharmaceuticals Inc. (the "Company") determined to commence a process to wind down the business of the Company. To that end, the Company is in discussion with creditors and vendors, and is making efforts to maximize the value of its assets. In connection with this process, the Company has suspended its pediatric Phase 2 clinical trial of ALTU-238, the Company’s hGH product candidate for growth hormone deficiency. In connection with the winding down, the Company is implementing a reduction in headcount of substantially all of its remaining employees on a phased basis in September and October of 2009.

Employees affected by the restructuring plan have received notification and will be provided with severance payments. Severance expenses will be paid in a lump sum.

The Company expects to record a restructuring charge of approximately $1.3 million in the third quarter of 2009 and $1.4 million in the fourth quarter of 2009, primarily representing cash payments for severance and related expenses. The Company may also incur further restructuring charges that could be significant due to events that may occur as a result of, or associated with, the restructuring plan, including the termination of contractual obligations and facilities-related costs.

Pretty steep drop after hours but I don't see any news. Did I miss something? I just kind of put this on a back burner and forgot about it, GLTA

.31 .... WITH .80 CASH? hmmmm. =)

Altus Pharma: Cash may be dry by OctoberBoston Business Journal - by Julie M. Donnelly

Altus Pharmaceuticals is set to run out of cash at the end of next month if the drug developer is unable to ink a partnership or other financial deal to remain as a going concern, according to a regulatory filing.

“As a result of our current cash position and in order to continue operating the company, Altus needs to raise additional capital before the end of September,” CEO Georges Gemayel said in a prepared written statement.

The company’s ash and cash equivalents balances as of June 30 totaled $8.1 million.

The Waltham, Mass.-based biotechnology company reported a loss of $4.9 million for the second quarter of 2009, down from a loss of $25.3 million in the second quarter of 2008. Research and development costs were slashed to $4.9 million in the second quarter of 2009 compared with $21.0 million in the second quarter of 2008.

Research and development expenses for the second quarter of 2009 decreased primarily due to discontinuing activities related to Altus’ Trizytek program in the first quarter of 2009. The company decided last quarter to stop work on the drug target for Cystic Fibrosis to focus its limited resources on another drug target for patients with growth hormone deficiency.

The Trizytek program reverted to the Cystic Fibrosis Foundation, and eventually found a home with Cambridge, Mass.-based Alnara Pharmaceuticals.

Altus also achieved savings due to the layoff of 70 percent of its staff in March, mostly of employees who had worked on the halted Trizytek program. The company recorded one-time restructuring charges of $5.1 million in the six months ended June 30, due mainly to the layoffs. On July 1, the company renegotiated the terms of its two facility leases as part of a move to consolidate its operations into one facility in the second quarter of 2009.

Altus’ (Nasdaq:ALTU) shares closed at $.37 Tuesday. The company is in danger of being delisted by the Nasdaq. On July 31, the stock exchange reinstituted its requirement that listed companies have share prices above a dollar.

We need VOLUME! No news, no VOLUME!...unless the MM's decide to set up a MOMO.

Started buying back some ALTU this week, not sure why, just have too much cash lying around.......

below 0.50 is a gift . this stock will spike over 1$ soon . don't miss the boat

Finally filled that old gap from 6 months ago, sold some more here, but it will head higher with time.

Brokeout today, even with that good chart movement, taking some off the table.

looking for that .468 break then its a buy, i remember this POS used to trade 20 bucks a share 2 years ago

http://www.stockta.com/cgi-bin/analysis.pl?symb=ALTU&num1=11&cobrand=&mode=stock+right

may be... there is a re-buy signal in 2 months chart... better loaded some in the .30's

GLTY

rebound? I like the chart of ALTU... nice trading today...

chart looks good for a run over .40 this week. Did talk to a doc who is quite familiar with growth hormones. Said ALTU-238 is practically a shoe in for approval. Doing more research it apears that would happen 2011-2012. 1 bil + potential. Even if the float is 100 mil in 2 years this could be a 30+ dollar stock.

played kerx and osci and dumped both for altu,i thinks its the better play at .30

Altus Pharmaceuticals Reports First Quarter 2009 Financial Results
On Monday May 11, 2009, 8:47 am EDT

WALTHAM, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU - News) today reported financial results for the quarter ended March 31, 2009.

First Quarter 2009 Results

For the first quarter of 2009, the Company reported a net loss attributable to common stockholders of $20.7 million, or $0.66 per share, compared to a net loss attributable to common stockholders of $24.6 million, or $0.80 per share, in the first quarter of 2008. Altus did not earn revenue for the first quarter of 2009 compared to reporting $2.6 million in the first quarter of 2008. The Company’s contract revenue in 2008 consisted of amounts earned under former collaborative research and development agreements relating to Trizytek and ALTU-238.

Research and development expense totaled $14.0 million in the first quarter of 2009 compared to $21.6 million in the first quarter of 2008. The decrease in R&D expense is primarily due to the completion of the Trizytek Phase 3 efficacy trial which was ongoing during the first quarter of 2008. General, sales and administrative expense totaled $3.4 million in the first quarter of 2009 compared to $5.8 million in the first quarter of 2008.

Cash, cash equivalents and marketable securities at March 31, 2009 were $25.0 million. Altus believes the current cash, cash equivalents and marketable securities position will last into September of 2009.

On January 26, 2009, Altus announced a strategic realignment to focus on the advancement of ALTU-238 and, to conserve capital resources, discontinue its Trizytek development activities. In connection with the realignment, the Company implemented a workforce reduction of approximately 70% of its workforce, primarily in functions related to the Trizytek program as well as certain general and administrative positions. As a result of these activities, the Company recognized a charge of $3.6 million in the first quarter of 2009, primarily for severance and related expenses. The Company anticipates taking a further restructuring charge of between $4.0 and $6.0 million in the second quarter of 2009.

“In early 2009 we implemented a strategic realignment of our product development priorities to focus on the advancement of ALTU-238, a once-per-week treatment for adult and pediatric patients with growth hormone deficiency,” stated Dr. Georges Gemayel, President and Chief Executive Officer of Altus Pharmaceuticals. “We believe that ALTU-238 represents a promising opportunity to make a major impact on the multi-billion dollar market for growth hormone replacement products.”

Gemayel continued, “As we continue to implement our realignment plan, we are negotiating the terms of certain obligations that are not associated with the current operating plan. One positive outcome resulting from these discussions is an agreement with Dr. Falk to settle our remaining financial obligation of €5.0 million. I am pleased to report that we will make a final settlement payment of €1.8 million in May 2009.”

ALTU-238 Program Update

ALTU-238 is being developed as a subcutaneously administered, once-per-week dosage formulation of recombinant human growth hormone (hGH) that can be administered through a fine gauge needle. Altus has successfully completed a Phase 2 trial with ALTU-238 in growth hormone deficient adult subjects and recently completed a Phase 1c trial confirming the safety, pharmacokinetic and pharmacodynamic profile of a single dose of weekly ALTU-238 compared to seven injections of daily growth hormone.

Dr. Gemayel concluded, “2009 is a crucial year for Altus. During the next several months, we will pursue additional funding to enable the ALTU-238 program to continue forward. In March we started a Phase 2 trial for ALTU-238 in growth hormone deficient pediatric subjects. We have initiated the majority of the 18 U.S. clinical sites that are participating in this clinical trial and they have begun screening patients. The target for enrollment is 36 growth hormone deficient pediatric patients.”

Conference Call Access Information

The Company will host a conference call to discuss its first quarter results at 11:00 a.m. ET on May 11. The call may be joined via telephone by dialing (877) 718-5101 or (719) 325-4772 (for international participants) at least 5 minutes prior to the start of the call. The conference confirmation code is: 7594867. For 72 hours following the call, an audio replay can be accessed by dialing (719) 457-0820 or (888) 203-1112 and using the conference confirmation code 7594867. A live audio webcast of the call will also be available on the "Investor Relations" section of the Company's website, www.altus.com. An archived audio webcast will be available on the Altus website approximately two hours after the event and will be archived for 30 days.

Powerful techs... doubled my position on Friday :D



Altus Pharmaceuticals to Host First Quarter Investor Conference Call on May 11, 2009
On Monday, May 11, 2009 before the market opens, Altus Pharmaceuticals Inc. (NASDAQ: ALTU) expects to report its results for the quarter ended March 31, 2009.

The Company will host a conference call to discuss the results at 11:00 a.m. ET on May 11. The call may be joined via telephone by dialing (877) 718-5101 or (719) 325-4772 (for international participants) at least 5 minutes prior to the start of the call. The conference confirmation code is: 7594867. For 72 hours following the call, an audio replay can be accessed by dialing (719) 457-0820 or (888) 203-1112 and using the conference confirmation code 7594867.

A live audio webcast of the call will also be available on the "Investor Relations" section of the Company's website, www.altus.com. An archived audio webcast will be available on the Altus website approximately two hours after the event and will be archived for 30 days.

About Altus Pharmaceuticals Inc.

Altus Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics. The Company's website is www.altus.com.




Altus Pharmaceuticals Inc.
Thomas Phair, 781-373-6432
Vice President, Finance




Source: Business Wire (May 8, 2009 - 9:24 AM EDT)

Highest volume so far this year today on this stock, good price action. next level of resistance is .60

Loaded up today at $0.25. I think ALTU is oversold at this point. Should see a leg up.

why do you think, it will go up into the 60's area? would be nice...

Nice little gap up this morning. I'm in from Friday. I think this will see 0.65 soon.

I wonder why the volume has been so strong over the last few days. Chart appears to be extremely positive with mid .60's next level of resistance.

I agree. Some strong buys this past week

After what CTIC did.. I can def see ALTU breaking .50 at least. Low float so she swings WILDLY!